A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cancer

Trial Profile

A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Apr 2014 Planned End Date changed from 1 Jan 2100 to 1 Jan 2010.
    • 20 Jul 2012 Planned end date changed from 1 Apr 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top